Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Change in Inventory (2023 - 2025)

Tarsus Pharmaceuticals has reported Change in Inventory over the past 3 years, most recently at $536000.0 for Q4 2025.

  • Quarterly results put Change in Inventory at $536000.0 for Q4 2025, up 336.12% from a year ago — trailing twelve months through Dec 2025 was $1.8 million (down 14.42% YoY), and the annual figure for FY2025 was $1.8 million, down 14.42%.
  • Change in Inventory for Q4 2025 was $536000.0 at Tarsus Pharmaceuticals, up from -$37000.0 in the prior quarter.
  • Over the last five years, Change in Inventory for TARS hit a ceiling of $3.1 million in Q4 2023 and a floor of -$227000.0 in Q4 2024.
  • Median Change in Inventory over the past 3 years was $594000.0 (2024), compared with a mean of $690400.0.
  • Peak annual rise in Change in Inventory hit 4246.67% in 2024, while the deepest fall reached 107.34% in 2024.
  • Tarsus Pharmaceuticals' Change in Inventory stood at $3.1 million in 2023, then plummeted by 107.34% to -$227000.0 in 2024, then soared by 336.12% to $536000.0 in 2025.
  • The last three reported values for Change in Inventory were $536000.0 (Q4 2025), -$37000.0 (Q3 2025), and $1.2 million (Q2 2025) per Business Quant data.